Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) and Evolus (NASDAQ:EOLS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.
Risk and Volatility
Sunshine Biopharma has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Valuation and Earnings
This table compares Sunshine Biopharma and Evolus”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sunshine Biopharma | $36.31 million | 0.02 | -$5.97 million | ($203.00) | -0.01 |
| Evolus | $297.18 million | 1.55 | -$51.64 million | ($0.47) | -14.85 |
Sunshine Biopharma has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 5.0% of Evolus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and target prices for Sunshine Biopharma and Evolus, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 1 | 1 | 0 | 0 | 1.50 |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
Evolus has a consensus target price of $15.00, suggesting a potential upside of 114.90%. Given Evolus’ stronger consensus rating and higher possible upside, analysts plainly believe Evolus is more favorable than Sunshine Biopharma.
Profitability
This table compares Sunshine Biopharma and Evolus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -17.94% | -26.36% | -20.60% |
| Evolus | -9.56% | N/A | -11.73% |
Summary
Evolus beats Sunshine Biopharma on 12 of the 14 factors compared between the two stocks.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
